Please ensure Javascript is enabled for purposes of website accessibility

Why Celldex Therapeutics and Momenta Pharmaceuticals Traded Down Today

By Brian Orelli, PhD - Feb 29, 2016 at 3:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a biotech thing.

What: Celldex Therapeutics (CLDX -15.80%) and Momenta Pharmaceuticals (MNTA) ended down about 10% today on no news.

So what: The era of volatile biotechs continues. Throw in some upcoming catalysts, and it's easy for momentum to take hold.

Celldex told investors to expect results from an interim check of the data from its ACT IV trial testing Rintega in glioblastoma in March. If you haven't looked at a calendar recently, March starts tomorrow, Fools.

Momenta is waiting for results in multiple lawsuits: one to see if it can sell its 3-times weekly version of Teva Pharmaceuticals Copaxone, and another to see if other generics infringe on its patents for making generic Lovenox.

Now what: Whether Celldex or Momenta is up 10% or down 10% on any given day is irrelevant to where their stock prices will be after these events.

For example, either the Data Safety and Monitoring Board will tell Celldex it can stop the trial because the drug is working, to stop because it isn't working, or to continue the trial. Investors have an idea of where the stock should trade after each of those outcomes, so where it trades now only changes the magnitude of the move for those who are planning on holding through the announcement.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
$22.70 (-15.80%) $-4.26
Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.